Chronic neurologic disturbance in childhood leukemia.
Twenty-three leukemic children were studied prospectively to detect chronic effects of therapy. All patients received CNS prophylaxis, including 2400 R cranial irradiation, and intermittent maintenance therapy with intravenous methotrexate, cyclophosphamide and cytosine arabinoside. Neurologic symptoms were observed in 12 patients, all of whom had intermittent limping and mild incoordination, between the 10th and 18th month of maintenance therapy. Five of the 12 sustained seizures and four of these had subsequent abnormalities in motor, perceptual, behavioral or language development. Three school-aged children have learning disability and perceptual-motor defects. Studies of CSF folate and MTX content are presented but not helpful in delineating the etiology of these neurologic symptoms.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D005492:Folic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D007859:Learning Disabilities / Q000209:etiology; D007938:Leukemia / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000628:therapy; D008727:Methotrexate / Q000134:cerebrospinal fluid; D009069:Movement Disorders / Q000209:etiology; D009422:Nervous System Diseases / Q000209:etiology*; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects*; D012640:Seizures / Q000209:etiology; D013997:Time Factors
D000970:Antineoplastic Agents; D003561:Cytarabine; D003520:Cyclophosphamide; D005492:Folic Acid; D008727:Methotrexate